Erik Anders Kronström
Chief Operating Officer chez INFANT BACTERIAL THERAPEUTICS AB
Fortune : 88 492 $ au 29/02/2024
Profil
Erik Anders Kronström occupies the position of Chief Operating Officer for Infant Bacterial Therapeutics AB.
In his past career he occupied the position of Chief Executive Officer for Biosergen AS.
He received a graduate degree from Royal Institute of Technology and an MBA from Warwick Business School.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
26/05/2023 | 11 194 ( 0,09% ) | 88 492 $ | 29/02/2024 |
Postes actifs de Erik Anders Kronström
Sociétés | Poste | Début |
---|---|---|
INFANT BACTERIAL THERAPEUTICS AB | Chief Operating Officer | 01/01/2018 |
Anciens postes connus de Erik Anders Kronström
Sociétés | Poste | Fin |
---|---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Chief Executive Officer | - |
Formation de Erik Anders Kronström
Warwick Business School | Masters Business Admin |
Royal Institute of Technology | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Biosergen AS
Biosergen AS BiotechnologyHealth Technology Biosergen AS develops drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. It develops antibiotics for the use in antifungal therapy. The firm uses engineered biosynthesis technology that allows alterations in microbial genes, which lead to predictable changes in the final structure of the natural product. The company was founded in 2004 and is headquartered in Tiller, Norway. | Health Technology |
Infant Bacterial Therapeutics AB |